Anthropic’s Gross Margin Flags Long-Term AI Profit Questions
• Anthropic, others raised at a valuation of 50-100 times forward revenue
• Major cloud providers will influence AI startups’ margins
The Takeaway
• AI startups may struggle to hold on to valuations based on revenue• Anthropic, others raised at a valuation of 50-100 times forward revenue
• Major cloud providers will influence AI startups’ margins
In the past year, artificial intelligence developer Anthropic has raised billions of dollars at a more than $15 billion valuation due to its fast revenue growth and big projections for future sales. But as Anthropic and scores of rivals mature, they’ll need to prioritize profit margins and cash flows if they want to build a sustainable business and have any hope of going public someday.
New data show that profit margins for such startups may end up lower than for existing enterprise software firms. After paying the costs of customer support and servers to power its AI, Anthropic’s gross margin—gross profit as a percentage of revenue—was between 50% and 55% in December, according to two people with direct knowledge of the figures. That’s far lower than the average gross margin of 77% for cloud software stocks, according to Meritech Capital.
And it may not improve much over time: At least one major Anthropic shareholder expects the company’s long-term gross margin to be around 60%, one of these people said.
Notably, Anthropic’s gross margin doesn’t reflect the server costs of training AI models, which Anthropic includes in its research and development expenses. These costs can add up to as much as $100 million per model, according to Sam Altman, CEO of OpenAI. An Anthropic spokesperson declined to comment.
The data suggest that the current breed of hot AI startup could face challenges in attracting future capital at the same prices that existing investors paid for shares as a multiple of the companies’ revenue. As companies get older, their valuation typically reflects their ability to generate cash. Right now, though, investors are focusing more on revenue growth for Anthropic, OpenAI and other young AI startups developing or enabling large language models. (See our Generative AI Database.)
These startups have been raising capital at a valuation of 50 to 100 times next year’s revenue, often due to their upbeat revenue projections. The median for publicly traded software companies, by contrast, is 6 times forward revenue, according to Meritech Capital. Those revenue multiples will be increasingly difficult for the startups to maintain as they get older.
Anthropic’s biggest startup rival, OpenAI, may have even weaker gross margins because it runs a heavily used free tier of its flagship chatbot, ChatGPT. That drives up server costs without generating additional revenue, although the free version likely helps OpenAI sell more monthly subscriptions than it would otherwise. After generating less than $30 million in revenue in 2022, OpenAI surpassed an annualized revenue pace of $1.6 billion as of December—an eye-popping growth rate. An OpenAI spokesperson declined to comment.
Anthropic, meanwhile, recently projected annualized revenue of at least $850 million by the end of 2024, after previously telling investors it would be generating $500 million in annualized revenue by then. It isn’t clear how much revenue Anthropic booked in 2023, the first year it began to generate revenue. It also isn’t clear how much money OpenAI and Anthropic are losing overall.
Rubber Meets Road
As long as the AI startups keep up that sort of momentum, investors can overlook their losses. That will likely end when revenue growth inevitably slips to 30% to 40% someday, said Tomasz Tunguz, a general partner at Theory Ventures, whose prior software investments have included Looker and Kustomer.
At that point, if a company’s cash flow from operations is negative with no near-term path to convert at least 10% of its revenue into cash flows, it’ll likely be harder to attract new investors, Tunguz said.
The growth and profit margin prospects of these startups rely in part on the major cloud providers that power their servers. Google and Amazon, which have each committed billions of dollars to Anthropic, sell its software to their cloud customers. It isn’t clear what kind of cut those cloud providers take when making such sales, but Anthropic probably generates better margins from selling its models directly to customers.
The prices the two cloud providers charge Anthropic for renting their cloud servers also have an impact on the startup’s margins. These numbers couldn’t be learned.
Microsoft’s investment in OpenAI offers a clue. As a cloud provider, Microsoft rents cloud servers to OpenAI at a relatively low margin, compared to other Microsoft cloud customers, said a person with knowledge of the situation. That helps keep down OpenAI’s server costs. As part of their deal, though, OpenAI must give Microsoft a cut of its direct sales to customers. And when Microsoft sells OpenAI software to its own cloud customers, it keeps a majority of revenue from those sales for itself. That could potentially become a problem as Microsoft increasingly draws enterprise customers that would otherwise buy software directly from OpenAI. The trend is likely eating into the startup’s growth rate.
For AI developers, the billion-dollar question is how quickly computing costs will continue to fall. Already, AI firms such as OpenAI have said they’ve cut the cost of running their AI models substantially over the past year by implementing new techniques for structuring the models, for instance. AI developers may also find it easier to run their models on cheaper servers rather than pay a pretty penny for state-of-the-art Nvidia servers. At the same time, it’s hard to predict such cost drops, as emerging models that are more computationally efficient could replace OpenAI’s LLMs.
Research Calls
-
Upgrades:
- Agree Realty (ADC) upgraded to Mkt Outperform from Mkt Perform at JMP Securities; tgt $71
- Allete (ALE) upgraded to Neutral from Sell at Guggenheim; tgt $58
- American Airlines (AAL) upgraded to Outperform from Peer Perform at Wolfe Research; tgt $17
- Avista (AVA) upgraded to Neutral from Sell at Guggenheim; tgt $34
- Digital Realty Trust (DLR) upgraded to Sector Outperform from Sector Perform at Scotiabank; tgt raised to $157
- Edison (EIX) upgraded to Buy from Neutral at Guggenheim; tgt $84
- Eversource Energy (ES) upgraded to Buy from Neutral at Guggenheim; tgt $72
- Fastly (FSLY) upgraded to Neutral from Sell at Citigroup; tgt raised to $20
- Intl Flavors (IFF) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $90
- NorthWestern (NWE) upgraded to Neutral from Sell at Guggenheim; tgt $47
- Norfolk Southern (NSC) upgraded to Outperform from Mkt Perform at Bernstein; tgt $272
- PagSeguro Digital (PAGS) upgraded to Neutral from Sell at Goldman; tgt raised to $13.80
- Pinnacle West (PNW) upgraded to Buy from Neutral at Guggenheim; tgt $78
- Plymouth Industrial REIT (PLYM) upgraded to Mkt Outperform from Mkt Perform at JMP Securities; tgt $27
- SentinelOne (S) upgraded to Buy from Neutral at BTIG Research; tgt $30
- Shoals Technologies (SHLS) upgraded to Equal Weight from Underweight at Barclays; tgt lowered to $15
- StoneCo (STNE) upgraded to Buy from Neutral at Goldman; tgt raised to $21
- TFI International (TFII) upgraded to Sector Outperform from Sector Perform at Scotiabank
- Union Pacific (UNP) upgraded to Outperform from Mkt Perform at Bernstein; tgt $280
-
Downgrades:
- Aclaris Therapeutics (ACRS) downgraded to Neutral from Buy at H.C. Wainwright
- Advanced Micro (AMD) downgraded to Market Perform from Outperform at Northland Capital
- Afya (AFYA) downgraded to Equal-Weight from Overweight at Morgan Stanley; tgt raised to $23
- American Electric (AEP) downgraded to Neutral from Buy at Guggenheim; tgt $81
- Archer-Daniels (ADM) downgraded to Neutral from Buy at Goldman; tgt lowered to $67
- Archer-Daniels (ADM) downgraded to Neutral from Outperform at Robert W. Baird; tgt lowered to $61
- Array Tech (ARRY) downgraded to Equal Weight from Overweight at Barclays; tgt lowered to $15
- CAE (CAE) downgraded to Sector Perform from Sector Outperform at Scotiabank
- Cadre Holdings (CDRE) downgraded to Mkt Perform from Outperform at Raymond James
- Comerica (CMA) downgraded to Mkt Perform from Outperform at Raymond James
- Commscope (COMM) downgraded to Underperform from Neutral at BofA Securities; tgt $2
- D.R. Horton (DHI) downgraded to Neutral from Buy at Seaport Research Partners
- DTE Energy (DTE) downgraded to Neutral from Buy at Guggenheim; tgt $111
- e.l.f. Beauty (ELF) downgraded to Equal-Weight from Overweight at Morgan Stanley; tgt raised to $168
- EPR Properties (EPR) downgraded to Mkt Perform from Mkt Outperform at JMP Securities
- Evergy (EVRG) downgraded to Neutral from Buy at Guggenheim; tgt $52
- Home Depot (HD) downgraded to Perform from Outperform at Oppenheimer
- IdaCorp (IDA) downgraded to Neutral from Buy at Guggenheim; tgt $93
- LCI Industries (LCII) downgraded to Underperform from Market Perform at BMO Capital Markets; tgt lowered to $100
- Linde plc (LIN) downgraded to Hold from Buy at Stifel; tgt $429
- Lowe's (LOW) downgraded to Perform from Outperform at Oppenheimer
- lululemon athletica (LULU) downgraded to Hold from Buy at HSBC Securities; tgt $500
- McCormick (MKC) downgraded to Equal Weight from Overweight at Consumer Edge Research
- Meritage (MTH) downgraded to Neutral from Buy at Seaport Research Partners
- Playtika (PLTK) downgraded to Hold from Buy at HSBC Securities; tgt $8
- Public Service (PEG) downgraded to Neutral from Buy at Guggenheim; tgt $61
- Taylor Morrison Home (TMHC) downgraded to Neutral from Buy at Seaport Research Partners
- Toll Brothers (TOL) downgraded to Neutral from Buy at Seaport Research Partners
- Tricon Residential (TCN) downgraded to Market Perform from Outperform at BMO Capital Markets
-
Others:
- Akamai Tech (AKAM) named on Positive Catalyst Watch at Citigroup
- Enovis Corporation (ENOV) initiated with a Buy at UBS; tgt $75
- EyePoint Pharmaceuticals (EYPT) initiated with an Overweight at JP Morgan; tgt $35
- Instacart (CART) initiated with a Buy at The Benchmark Company; tgt $32
- NiSource (NI) initiated with an Overweight at Barclays; tgt $28
- The Vita Coco Company (COCO) downgraded to Mkt Perform from Outperform at William Blair
- Worthington Enterprises (WOR) initiated with a Sell at Goldman; tgt $50
Gapping down
News:
- ADM -13.2% (names Ismael Roig interim CFO; issues FY23 outlook below consensus)
- BNOX -11.4% (provides a review of 2023 and of 2024 plans)
- RILY -11.3% (Issues Statement in response to a Bloomberg News article)
- FUSN -5.7% (increases its previously disclosed Open Market Sale Agreement to $200 mln)
- HTHT -4.4% (announces preliminary results for hotel operations in Q4)
- BA -1.5% (FAA provides updates on grounding of Boeing 737 MAX 9 aircraft)
- NMG -1.4% (Mason Resources entered into an asset purchase agreement dated January 21 2024 with NMG for the sale of the Lac Guéret Property targeted for the development of the Uatnan Mining Project)
- ACIU -1.2% (to regain all global rights to the anti-amyloid beta antibody crenezumab and the anti-Tau antibody semorinemab following termination of collaboration agreements with Genentech)
- TLYS -1.1% (Ed Thomas has retired from his position as President and Chief Executive Officer and as a Director)
- IDYA -0.9% (entered into an Open Market Sales Agreement)
Analyst comments:
- COMM -3.8% (downgraded to Underperform from Neutral at BofA Securities)
- ARRY -2.6% (downgraded to Equal Weight from Overweight at Barclays)
- HD -0.8% (downgraded to Perform from Outperform at Oppenheimer)
- TMHC -0.8% (downgraded to Neutral from Buy at Seaport Research Partners)
- LOW -0.7% (downgraded to Perform from Outperform at Oppenheimer)
- LULU -0.6% (downgraded to Hold from Buy at HSBC Securities)
- TOL -0.6% (downgraded to Neutral from Buy at Seaport Research Partners)
Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PK +1.3% (guidance)
Other news:
- CHRS +16.4% (to divest ophthalmology franchise to Sandoz (SDZNY) in $170 mln upfront all cash dea)
- PHVS +15.4% (FDA lifting of the clinical hold of deucrictibant for the prophylactic treatment of HAE attacks)
- SGMT +8.5% (Topline Results from Phase 2b FASCINATE-2 Clinical Trial)
- AUTL +6.2% (acceptance of Biologics License Application for obecabtagene autoleucel)
- PROK +5.4% (files for $100 mln Open Market Sale Agreement relating to its Class A ordinary shares)
- SEDG +5% (announces 16% global workforce reduction)
- M +4.3% (Board of Directors Responds to Unsolicited Non-Binding Proposal from Arkhouse and Brigade; Arkhouse issues statement on Macy's)
- CELH +2.4% (announced its expansion into new international markets)
- IONS +2% (topline results from Phase 3 OASIS-HAE study)
- LDI +1.8% (provides supplemental information regarding the cybersecurity incident)
- ARWR +1.5% (Chief Medical Officer to depart)
- MANU +1.4% (names Omar Berrada as new CEO)
- SAVE +1.3% (JetBlue Airways and Spirit Airlines file notice of appeal)
- ATHE +1.1% (issues shareholder letter highlighting pipeline advances and key upcoming milestones)
- GNK +1% (Highlights Steps the Company Is Taking to Drive Sustainable, Long-Term Shareholder Value)
- PHI +1% (confirms the statement of the Chairman that PLDT is eyeing a lower capex number for 2024)
- SONY +0.9% (unit ends merger plans with Zee Entertainment Enterprises)
Analyst comments:
- S +7.3% (upgraded to Buy from Neutral at BTIG Research)
- FSLY +4.7% (upgraded to Neutral from Sell at Citigroup)
- PAGS +3.4% (upgraded to Neutral from Sell at Goldman)
- STNE +3.1% (upgraded to Buy from Neutral at Goldman)
- SHLS +2.4% (upgraded to Equal Weight from Underweight at Barclays)
- IFF +1.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- NSC +1% (upgraded to Outperform from Mkt Perform at Bernstein)
- UNP +0.9% (upgraded to Outperform from Mkt Perform at Bernstein)
Early premarket gappers
-
Gapping up:
- CHRS +24.6%, SEDG +5.9%, SAVE +5.7%, PROK +3.8%, CELH +3.2%, M +2.9%, LDI +1.8%, ARWR +1.5%, SONY +1.3%, GNK +1%, BNOX +1%, BMY +0.8%
-
Gapping down:
- RILY -17.7%, ADM -14.2%, FUSN -5.8%, HTHT -4.9%, BA -2.5%, MGNI -2.2%, TLYS -1.1%, JBLU -0.8%
Occidental Petro discloses it received a request for additional information and documentary material from the FTC regarding merger with CrownRock Holdings (56.42)
- As previously disclosed, on December 10, 2023, OXY entered into a Partnership Interest Purchase Agreement (the "Purchase Agreement") with CrownRock Holdings, L.P., a Delaware limited partnership ("Limited Partner"), CrownRock GP, LLC, a Delaware limited liability company ("General Partner" and, together with the Limited Partner, the "Sellers"), Coral Holdings LP, LLC, a Delaware limited liability company and a wholly owned indirect subsidiary of Occidental ("LP Purchaser"), and Coral Holdings GP, LLC, a Delaware limited liability company and wholly owned indirect subsidiary of Occidental ("GP Purchaser," together with the LP Purchaser, the "Purchasers"). Subject to the terms and conditions of the Purchase Agreement, the Purchasers will purchase 100% of the issued and outstanding partner interests of CrownRock, L.P., a Delaware limited partnership ("CrownRock"), from the Sellers (such transaction, the "Acquisition" and, together with the other transactions contemplated by the Purchase Agreement, the "Transactions").
- The Acquisition is conditioned on, among other things, the expiration or termination of the waiting period (and any extensions thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"). Pursuant to the HSR Act, Occidental and the Sellers filed notification and report forms with the Department of Justice and the Federal Trade Commission (the "FTC").
- On January 19, 2024, Occidental and the Sellers each received a request for additional information and documentary material (each, a "Second Request") from the FTC in connection with the FTC's review of the Acquisition. A Second Request extends the waiting period imposed by the HSR Act until 30 days after each of Occidental and the Sellers have substantially complied with the Second Request issued to them, unless that period is extended voluntarily by Occidental and the Sellers or terminated sooner by the FTC. Occidental and the Sellers continue to work constructively with the FTC in its review of the Acquisition.
Abivax SA provides 2024 strategic outlook and lays out key milestones over next 12 months (11.57)
- Induction data read-out expected Q1 2025 from the pivotal Phase 3 ABTECT program evaluating obefazimod in moderately to severely active ulcerative colitis (UC)
- Formal process evaluating oral and injectable combination therapy candidates with obefazimod in UC has commenced; preclinical data to support decision-making on combination agent expected in 2H 2024
- Top-line data from long-term extension trial with 25mg obefazimod once-daily oral after one and two years of treatment expected to read-out in Q3 2024
- IND for Phase 2 trial of obefazimod in Crohn's disease (CD) cleared; Abivax to consider protocol modifications based on FDA recommendations
- Obefazimod follow-on candidate selection expected in Q3 2024